1
|
Ito A, Shinkai M, Honda H and Kobayashi T:
Medical application of functionalized magnetic nanoparticles. J
Biosci Bioeng. 100:1–11. 2005. View Article : Google Scholar
|
2
|
Motoyama J, Yamashita N, Morino T, Tanaka
M, Kobayashi T and Honda H: Hyperthermic treatment of DMBA-induced
rat mammary cancer using magnetic nanoparticles. Biomagn Res
Technol. 6:22008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Muralidharan V, Malcontenti-Wilson C and
Christophi C: Interstitial laser hyperthermia for colorectal liver
metastases: the effect of thermal sensitization and the use of a
cylindrical diffuser tip on tumor necrosis. J Clin Laser Med Surg.
20:189–196. 2002. View Article : Google Scholar
|
4
|
Patrício MB, Soares J and Vilhena M:
Morphologic and morphometric studies on tumor necrosis produced by
radiotherapy, and hyperthermia singly and in combination. J Surg
Oncol. 42:5–10. 1989.PubMed/NCBI
|
5
|
Tschoep-Lechner KE, Milani V, Berger F, et
al: Gemcitabine and cisplatin combined with regional hyperthermia
as second-line treatment in patients with gemcitabine-refractory
advanced pancreatic cancer. Int J Hyperthermia. 29:8–16. 2013.
View Article : Google Scholar
|
6
|
Nikfarjam M, Malcontenti-Wilson C and
Christophi C: Focal hyperthermia produces progressive tumor
necrosis independent of the initial thermal effects. J Gastrointest
Surg. 9:410–417. 2005. View Article : Google Scholar
|
7
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Tabernero J: The role of VEGF and EGFR
inhibition: implications for combining anti-VEGF and anti-EGFR
agents. Mol Cancer Res. 5:203–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar
|
10
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Fajardo LF, Prionas SD, Kowalski J and
Kwan HH: Hyperthermia inhibits angiogenesis. Radiat Res.
114:297–306. 1988. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Roca C, Primo L, Valdembri D, et al:
Hyperthermia inhibits angiogenesis by a plasminogen activator
inhibitor 1-dependent mechanism. Cancer Res. 63:1500–1507.
2003.PubMed/NCBI
|
13
|
Johannsen M, Thiesen B, Jordan A, et al:
Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in
the orthotopic Dunning R3327 rat model. Prostate. 64:283–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhang S, Bian Z, Gu C, et al: Preparation
of anti-human cardiac troponin I immunomagnetic nanoparticles and
biological activity assays. Colloids Surf B Biointerfaces.
55:143–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang ZY, Song J and Zhang DS: Nanosized
As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia
selectively target liver cancer cells. World J Gastroenterol.
15:2995–3002. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Müller S: Magnetic fluid hyperthermia
therapy for malignant brain tumors - an ethical discussion.
Nanomedicine. 5:387–393. 2009.PubMed/NCBI
|
17
|
Yan S, Zhang D, Gu N, et al: Therapeutic
effect of Fe2O3 nanoparticles combined with magnetic fluid
hyperthermia on cultured liver cancer cells and xenograft liver
cancers. J Nanosci Nanotechnol. 5:1185–1192. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Johannsen M, Thiesen B, Gneveckow U, et
al: Thermotherapy using magnetic nanoparticles combined with
external radiation in an orthotopic rat model of prostate cancer.
Prostate. 66:97–104. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Johannsen M, Jordan A, Scholz R, et al:
Evaluation of magnetic fluid hyperthermia in a standard rat model
of prostate cancer. J Endourol. 18:495–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Jordan A, Scholz R, Wust P, et al: Effects
of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in
vivo. Int J Hyperthermia. 13:587–605. 1997. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bottini A, Berruti A, Bersiga A, et al:
Changes in microvessel density as assessed by CD34 antibodies after
primary chemotherapy in human breast cancer. Clin Cancer Res.
8:1816–1821. 2002.PubMed/NCBI
|
22
|
de la Taille A, Katz AE, Bagiella E, et
al: Microvessel density as a predictor of PSA recurrence after
radical prostatectomy. A comparison of CD34 and CD31. Am J Clin
Pathol. 113:555–562. 2000.PubMed/NCBI
|
23
|
Ruan J, Hyjek E, Kermani P, et al:
Magnitude of stromal hemangiogenesis correlates with histologic
subtype of non-Hodgkin’s lymphoma. Clin Cancer Res. 12:5622–5631.
2006.PubMed/NCBI
|
24
|
Sawaji Y, Sato T, Takeuchi A, Hirata M and
Ito A: Anti-angiogenic action of hyperthermia by suppressing gene
expression and production of tumour-derived vascular endothelial
growth factor in vivo and in vitro. Br J Cancer. 86:1597–1603.
2002. View Article : Google Scholar : PubMed/NCBI
|